HAVN Life Sciences Inc. (HAVLF)
- Previous Close
0.0112 - Open
0.0112 - Bid --
- Ask --
- Day's Range
0.0112 - 0.0112 - 52 Week Range
0.0060 - 0.1500 - Volume
33 - Avg. Volume
2,962 - Market Cap (intraday)
326,446 - Beta (5Y Monthly) -0.73
- PE Ratio (TTM)
-- - EPS (TTM)
-2.2600 - Earnings Date Apr 19, 2024 - Apr 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is headquartered in Richmond, Canada.
www.havnlife.comRelated News
Performance Overview: HAVLF
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HAVLF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HAVLF
Valuation Measures
Market Cap
165.07k
Enterprise Value
173.93k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.19
Price/Book (mrq)
0.27
Enterprise Value/Revenue
0.30
Enterprise Value/EBITDA
-0.01
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.27%
Return on Equity (ttm)
-234.52%
Revenue (ttm)
586.98k
Net Income Avi to Common (ttm)
-15.71M
Diluted EPS (ttm)
-2.2600
Balance Sheet and Cash Flow
Total Cash (mrq)
13.99k
Total Debt/Equity (mrq)
3.13%
Levered Free Cash Flow (ttm)
-708.92k